BioCryst Pharmaceuticals is trading 9.0% down at $7.30 in pre-market, with no specific catalyst identified.
- No clear company-specific announcement explaining the October 16, 2026, decline surfaced in available search results.
- The investor-relations feed lists an October 5 advisory-board announcement as its latest press release.
- Market context is mixed and does not establish a macro explanation for the drop.